COMy 2023 | The value of ixazomib in the treatment of older, frail patients with multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the value of ixazomib in the treatment of older, frail patients with multiple myeloma. Dr Richardson highlights findings from a study evaluating ixazomib in combination with pomalidomide and dexamethasone in patients with relapsed/refractory (R/R) disease, which demonstrated a progression-free survival (PFS) benefit in patients receiving the ixazomib combination versus those in the control arm. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda
Oncopeptides, Celgene/BMS, Karyopharm, Takeda
